Affinage

MME

Neprilysin · UniProt P08473

Length
750 aa
Mass
85.5 kDa
Annotated
2026-06-10
100 papers in source corpus 20 papers cited in narrative 20 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/7 claims corpus-supported (86%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

MME encodes neprilysin (NEP/CD10/CALLA), a zinc-dependent cell-surface neutral endopeptidase (EC 3.4.24.11) whose phosphoramidon-inhibitable enzymatic activity cleaves bioactive peptides at the plasma membrane to attenuate peptide-mediated signaling across diverse cell types (PMID:2531122, PMID:1833412). On neutrophils, surface NEP hydrolyzes inflammatory peptides such as f-MLP and substance P, and inhibiting its activity potentiates peptide-driven migration and adhesion-molecule changes (CD11b/CD18 upregulation, LAM-1 shedding), establishing NEP as a brake on inflammatory responsiveness (PMID:1717072). The same catalytic mechanism limits peptide-mitogen signaling to constrain proliferation: NEP cleaves thymopentin to restrain thymic epithelial cell growth (PMID:9337153), and its inhibition or loss accelerates non-small-cell lung carcinoma and gastric carcinoma proliferation (PMID:7962523). NEP also regulates cell-fate decisions, maintaining mammary progenitors in an undifferentiated state through its protease activity acting together with beta1-integrin adhesion (PMID:20692264), and it suppresses esophageal squamous carcinoma metastasis by inhibiting FAK phosphorylation and the downstream FAK-RhoA motility axis (PMID:31054987). NEP associates selectively with the tetraspanin CD9, which promotes its release in exosomes/microvesicles without altering its intrinsic peptidase activity (PMID:23289620). Loss-of-function MME mutations cause late-onset axonal peripheral neuropathy through both autosomal-recessive (AR-CMT2T) and incompletely penetrant autosomal-dominant inheritance, with reduced neprilysin protein and enzymatic activity confirmed in patient nerve and blood (PMID:26991897, PMID:27588448, PMID:33144514); truncating maternal mutations also underlie antenatal membranous glomerulonephritis via fetomaternal alloimmunization against podocyte NEP (PMID:15464186). A common Val73 variant allozyme misfolds and is degraded by proteasomal and autophagic pathways with chaperone (BiP/GRP94) induction, providing a molecular basis for reduced enzyme availability (PMID:20692264).

Mechanistic history

Synthesis pass · year-by-year structured walk · 11 steps
  1. 1989 High

    Established that the leukemia/glioma surface antigen CD10/cALLA is itself an enzymatically active neutral endopeptidase, unifying an immunophenotypic marker with a defined catalytic activity.

    Evidence Phosphoramidon-inhibitable endopeptidase assay, anti-NEP/anti-cALLA immunostaining, and NEP mRNA Northern blot across glioma cell lines

    PMID:1833412 PMID:2531122

    Open questions at the time
    • Did not enumerate the physiological peptide substrates in these cells
    • Structural basis of catalysis not addressed
  2. 1991 High

    Defined NEP/CD10 as a regulator of neutrophil inflammatory responsiveness by degrading chemotactic and inflammatory peptides at the cell surface.

    Evidence Cell-based enzyme inhibition with migration and adhesion-molecule (CD11b/CD18, LAM-1) flow cytometry readouts in neutrophils

    PMID:1717072

    Open questions at the time
    • Did not identify which substrate dominates in vivo
    • Mechanism coupling neutrophil activation state to NEP activity unresolved
  3. 1994 Medium

    Extended the peptide-degradation logic to a growth-control role, showing NEP limits peptide-mitogen-driven proliferation of carcinoma cells.

    Evidence CD10/NEP inhibition proliferation assays inversely correlated with PCNA in NSCLC; gastric cancer lines confirmed pharmacologically

    PMID:15492809 PMID:7962523

    Open questions at the time
    • Specific mitogenic substrate not definitively identified
    • Gastric finding rests on a single inhibition assay
  4. 1997 Medium

    Provided substrate-resolved evidence that NEP cleavage of a defined peptide (thymopentin) tunes cell proliferation.

    Evidence Phosphoramidon synergy with TP5 and surface peptide-cleavage assays in thymic epithelial cell lines

    PMID:9337153

    Open questions at the time
    • Downstream TP5 receptor signaling not mapped
    • Single cell-line system
  5. 2004 High

    Demonstrated in humans that complete loss of NEP protein has pathological consequences, identifying NEP as the podocyte antigen in antenatal membranous glomerulonephritis.

    Evidence Genomic sequencing of truncating MME mutations in mothers plus anti-NEP IgG subclass analysis across families

    PMID:15464186

    Open questions at the time
    • Does not address NEP catalytic role in the kidney
    • Penetrance of alloimmunization not quantified
  6. 2010 High

    Linked a common MME coding variant to reduced enzyme availability via protein misfolding and degradation, giving a mechanistic basis for functional NEP deficiency.

    Evidence COS-1 expression of Val73 allozyme with quantitative Western blot, fluorometric activity assay, proteasome/autophagy inhibitors, and BiP/GRP94 analysis

    PMID:20692264

    Open questions at the time
    • Physiological/clinical penetrance of the variant not established here
    • Folding defect inferred from crystal-structure prediction, not directly imaged
  7. 2010 Medium

    Showed NEP protease activity actively maintains the mammary progenitor pool, expanding its role from signal attenuation to stem-cell fate control.

    Evidence FACS isolation of CD10-high/EpCAM-low cells, mammosphere assays, and enzyme inhibition driving differentiation

    PMID:20506111

    Open questions at the time
    • Relevant cleaved substrate maintaining progenitors unknown
    • Mechanistic interplay with beta1-integrin not molecularly resolved
  8. 2013 High

    Identified the tetraspanin CD9 as a direct surface partner controlling NEP packaging into exosomes/microvesicles, separating trafficking from intrinsic catalysis.

    Evidence Co-IP, CD9/CD82 chimera mutagenesis, shRNA knockdown, and exosome quantification with independent peptidase assays

    PMID:23289620

    Open questions at the time
    • Functional consequence of NEP exosomal release on recipient cells not tested
    • CD9-binding interface on NEP not mapped
  9. 2016 High

    Established MME loss-of-function as a genetic cause of late-onset axonal neuropathy through both recessive and dominant, incompletely penetrant inheritance, with NEP reduction confirmed in patient nerve.

    Evidence Whole-exome/Sanger sequencing across multiple cohorts plus immunohistochemical and enzymatic confirmation in peripheral nerve; one family showed a disulfide-disrupting p.C143Y in SCA43

    PMID:26991897 PMID:27583304 PMID:27588448

    Open questions at the time
    • NEP substrate(s) relevant to axonal maintenance not identified
    • Basis of incomplete penetrance unresolved
    • C143Y functional consequence inferred from structure, not assayed
  10. 2019 Medium

    Defined a non-proteolytic-context tumor-suppressor mechanism in which MME restrains metastasis by inhibiting FAK-RhoA signaling and cell adhesion.

    Evidence MME overexpression in vitro/in vivo metastasis assays with Western blot for FAK phosphorylation and RhoA pathway analysis in ESCC

    PMID:31054987

    Open questions at the time
    • Whether enzymatic activity is required for FAK inhibition not dissected
    • Single cancer-type, single lab
  11. 2023 Medium

    Positioned MME as a marker of progenitor subpopulations with distinct fate biases, including adipogenic FAPs refractory to WNT-mediated suppression and CD10+ adventitial osteogenic progenitors.

    Evidence scRNA/snRNA-seq, transplantation, and WNT/hedgehog pathway perturbation in FAP and adventitial progenitor systems

    PMID:31721342 PMID:36707617

    Open questions at the time
    • Whether NEP enzymatic activity drives these fate outcomes or is merely a marker is unclear
    • Substrates relevant to FAP/adventitial biology not identified

Open questions

Synthesis pass · forward-looking unresolved questions
  • The physiological substrate(s) of neprilysin whose accumulation drives axonal neuropathy, and whether catalytic versus scaffolding functions account for its progenitor and tumor-suppressor roles, remain unresolved.
  • No defined substrate links NEP loss to axon degeneration
  • Catalytic vs non-catalytic contribution to FAK-RhoA inhibition and progenitor maintenance not separated
  • No structural model of NEP-CD9 or variant misfolding directly validated

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016787 hydrolase activity 5 GO:0140096 catalytic activity, acting on a protein 3 GO:0008092 cytoskeletal protein binding 1
Localization
GO:0005886 plasma membrane 4 GO:0031410 cytoplasmic vesicle 1
Pathway
R-HSA-1643685 Disease 4 R-HSA-1266738 Developmental Biology 3 R-HSA-162582 Signal Transduction 2 R-HSA-168256 Immune System 1
Partners
CD9

Evidence

Reading pass · 20 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1991 CD10/NEP (neutral endopeptidase 24.11) enzymatic activity on neutrophil cell surfaces hydrolyzes inflammatory peptides including f-MLP and substance P, thereby controlling neutrophil responsiveness; inhibition of CD10/NEP enzymatic activity potentiates f-MLP- and substance P-induced changes in neutrophil morphology, migration, and adhesion molecule expression (upregulation of Mo1/CD11b/CD18 and shedding of LAM-1). CD10/NEP enzymatic activity is itself regulated by the activation state of the neutrophil. Cell-based enzyme inhibition assays, flow cytometry for adhesion molecules, neutrophil migration assays Blood High 1717072
1989 cALLA (CD10) expressed on glioma cell lines is enzymatically active neutral endopeptidase (NEP), as demonstrated by phosphoramidon-inhibitable endopeptidase activity and the presence of NEP-specific mRNA; surface expression of cALLA directly correlates with functional NEP enzymatic activity. Enzyme activity assay with phosphoramidon inhibition, immunostaining with anti-NEP and anti-cALLA antibodies, Northern blot for NEP mRNA International journal of cancer High 2531122
1991 CALLA (CD10) is structurally identical to neutral endopeptidase 3.4.24.11 (NEP); malignant leukemic cells express a functionally active NEP enzyme, and surface CD10 expression correlates with NEP enzymatic activity. No gross alteration in the CD10/CALLA gene was found in leukemic or malignant cell lines. Restriction enzyme hybridization (Southern blot), enzyme activity assays for NEP on leukemia samples and cell lines Journal of cellular physiology Medium 1833412
1994 CD10/NEP modulates peptide-mediated proliferation of non-small cell lung carcinoma (NSCLC) cells; cells with lower CD10/NEP expression proliferate more rapidly, and inhibition of cell-surface CD10/NEP enzymatic activity increases cellular growth rate. CD10/NEP expression is inversely correlated with proliferating cell nuclear antigen (PCNA) expression, and NSCLC cells express receptors for mitogenic peptide substrates of CD10/NEP. Immunostaining for CD10/NEP and PCNA, cell proliferation assays with CD10/NEP inhibition, receptor characterization The Journal of clinical investigation Medium 7962523
1997 CD10 (endopeptidase 24.11) expressed on thymic epithelial cell (TEC) lines cleaves the thymic peptide thymopentin-5 (TP5) at the cell surface, thereby modulating TP5-induced TEC proliferation. Phosphoramidon, a specific endopeptidase 24.11 inhibitor, acts in synergy with TP5 to enhance TEC growth, confirming that CD10-mediated TP5 cleavage limits TP5 mitogenic signaling. Enzyme inhibition with phosphoramidon, cell proliferation assays, peptide cleavage assays at TEC surface FASEB journal Medium 9337153
1998 Human cytomegalovirus (HCMV) infection downregulates CD10 (neutral endopeptidase) surface expression and enzyme activity; HCMV reduces CD10 mRNA levels, inhibits glycosylation of newly synthesized CD10 polypeptide chains, and decreases the rate of CD10 synthesis. Downregulation of CD10 by HCMV is independent of viral DNA synthesis (treatment with viral DNA synthesis inhibitor does not block CD10 downregulation), suggesting a mechanism distinct from that used for CD13 downregulation. Flow cytometry for surface expression, enzyme activity assays, metabolic labeling, RT-PCR/Northern blot for mRNA, inhibitor studies Virology Medium 9792845
2000 NEP/CD10 is expressed on syncytiotrophoblasts of normal placenta and in gestational trophoblastic diseases (GTDs). NEP enzyme activity in choriocarcinoma cell lines correlates with cell-surface NEP protein levels and is abolished by the NEP inhibitor phosphoramidon. NEP appears as a double band of 95 and 100 kDa in placental and GTD tissues. Differential localization of NEP among trophoblastic tumors (restricted to syncytiotrophoblasts in normal placenta and hydatidiform mole; extended to anaplastic cytotrophoblasts in choriocarcinoma) suggests a role in trophoblast transformation and hCG secretion. Flow cytometry, phosphoramidon enzyme inhibition assay, immunoblot (Western blot), immunohistochemistry Laboratory investigation Medium 11092533
2002 NEP/CD10 expression is induced de novo on HL-60 cells upon jaspamide (jasplakinolide)-induced apoptosis. Once expressed, CD10 enzyme activity interferes with apoptotic signaling: inhibition of CD10 enzymatic activity (by phosphoramidon or anti-CD10 antibody) significantly increases apoptosis. CD10 expression is blocked by monocytic differentiating agents (vitamin D3, PMA) but not granulocytic agents, linking CD10 expression to granulocytic differentiation. A broad-spectrum caspase inhibitor partially blocks CD10 induction, suggesting a connection between apoptosis and CD10 synthesis. Flow cytometry, cycloheximide protein synthesis inhibition, enzyme inhibition (phosphoramidon, anti-CD10 antibody), caspase inhibitor studies, differentiation agent treatments Cellular and molecular life sciences Medium 12363040
2004 Truncating mutations in the MME gene (encoding NEP/CD10) cause absence of NEP protein expression in affected mothers, leading to fetomaternal alloimmunization against fetal NEP antigens on glomerular podocytes during pregnancy. Two compound heterozygous or homozygous mutations were identified (1342C→T nonsense and 446delC frameshift). The severity of neonatal membranous glomerulopathy was determined by the maternal IgG response to fetal NEP, establishing NEP as the podocyte target antigen in antenatal membranous glomerulonephritis. Direct sequencing of genomic PCR products, SNP haplotype analysis, Western blotting for IgG subclasses with anti-NEP activity Lancet High 15464186
2010 CD10 protease activity is required to prevent differentiation of human mammary progenitors: inhibition of CD10 enzymatic activity promotes differentiation. The CD10-high/EpCAM-low population is enriched for early common progenitors and mammosphere-forming cells. CD10 acts in concert with beta1-integrin adhesion to the basement membrane to maintain the mammary progenitor/stem cell pool. Cell sorting (FACS for CD10 and EpCAM), mammosphere formation assays, enzyme inhibition functional assays, in vitro lineage progression assay Stem cells Medium 20506111
2010 A common MME nonsynonymous variant (Val73) causes a significant reduction in MME enzyme activity (21% of wild-type) and immunoreactive NEP protein (29% of wild-type). Proteasome-mediated degradation and autophagy both participate in the degradation of this variant allozyme, and upregulation of chaperone proteins BiP and GRP94 after Val73 MME transfection indicates protein misfolding, consistent with MME X-ray crystal structural predictions. COS-1 cell transfection, quantitative Western blot, fluorometric enzyme activity assay, proteasome/autophagy inhibitor studies, chaperone protein analysis Journal of molecular and cellular cardiology High 20692264
2013 CD10 is selectively associated with tetraspanin CD9 (but not CD82) on the cell surface. Stable expression of wild-type CD9 in CD10-positive K562 cells enhances CD10 release with exosomes five-fold, whereas CD9 chimera containing the CD82 C-terminal tail has little effect. ShRNA knockdown of CD9 in Nalm-6 pre-B cells reduces endogenous CD10 release in microvesicles two-fold. CD10 peptidase activity correlates with CD10 expression level and is not significantly modulated by CD9 expression per se. Co-immunoprecipitation, chimeric tetraspanin mutagenesis, shRNA knockdown, exosome isolation and quantification, peptidase activity assay The FEBS journal High 23289620
2016 Recessive loss-of-function mutations in MME (encoding neprilysin/NEP) cause autosomal-recessive Charcot-Marie-Tooth type 2 (AR-CMT2T) with late-onset axonal neuropathy; lack/decrease of NEP protein expression was confirmed in peripheral nerve tissue of affected patients. All MME mutations identified were consistent with loss-of-function. The loss-of-function MME mutation did not cause early-onset Alzheimer's disease in affected individuals. Whole-exome sequencing, Sanger sequencing mutation confirmation, immunohistochemical protein expression in peripheral nerve, clinico-pathological characterization Annals of neurology High 26991897
2016 Rare heterozygous loss-of-function and missense mutations in MME (neprilysin) cause late-onset autosomal-dominant axonal polyneuropathies with age-related incomplete penetrance. MME mutations result in strongly decreased tissue availability of neprilysin and impaired enzymatic activity in affected individuals. Whole-exome sequencing, Sanger sequencing, nerve tissue neprilysin level measurement, enzymatic activity assay in patient tissue American journal of human genetics High 27588448
2016 A heterozygous MME missense mutation (p.C143Y), affecting a conserved cysteine involved in a disulfide bridge of neprilysin, segregates with dominant spinocerebellar ataxia and polyneuropathy (SCA43) in a five-generation Belgian family, indicating that disruption of this structural disulfide bridge causes dominant disease. Linkage analysis, whole-exome sequencing, Sanger sequencing cosegregation analysis, bioinformatic conservation analysis Neurology Genetics Medium 27583304
2019 MME (neprilysin/CD10) inhibits esophageal squamous cell carcinoma (ESCC) metastasis by inhibiting FAK phosphorylation and thereby disrupting the FAK-RhoA signaling axis, which is important for cell movement. MME overexpression also interrupts ESCC tumor cell adhesion. In vitro and in vivo metastasis assays, Western blot for FAK phosphorylation, RhoA pathway analysis, MME overexpression functional studies The American journal of pathology Medium 31054987
2019 CD10 expression identifies a subset of human adventitial perivascular progenitor cells (CD10+ adventitial cells) with higher proliferation, clonogenic, and osteogenic potentials compared to CD10- counterparts. CD10+ adventitial cells increase expression of cell cycle protein CCND2 via ERK1/2 signaling and osteoblastogenic gene expression via NF-κB signaling. CD10 expression in adventitial cells is upregulated through sonic hedgehog-mediated GLI1 signaling. Cell sorting, clonogenic assays, osteogenic differentiation assays, Western blotting for ERK1/2 and NF-κB pathway components, hedgehog pathway inhibition Stem cells Medium 31721342
2020 MME variants are the most frequently identified genetic cause of late-onset unexplained axonal neuropathies, accounting for 34.8% of genetically solved cases; transmission is consistent with incompletely penetrant autosomal-dominant inheritance. Low neprilysin blood levels were confirmed in patients with MME variants, supporting a loss-of-function mechanism. Whole-exome sequencing, MME single-gene sequencing, blood neprilysin protein level measurement Neurology High 33144514
2023 An MME+ fibro-adipogenic progenitor (FAP) subpopulation has high adipogenic potential and low WNT pathway activity, making it refractory to WNT activator-mediated inhibition of adipogenic commitment. Transplantation experiments confirmed that MME+ FAPs preferentially differentiate into adipocytes under pathological conditions, and MME+ FAPs undergo apoptosis during muscle regeneration, reducing their abundance. Single-nuclei and single-cell RNA sequencing, ex vivo cell characterization, transplantation experiments, WNT pathway inhibitor/activator studies Communications biology Medium 36707617
2004 Inhibition of CD10 enzymatic activity significantly reduced the growth of gastric cancer cell lines MKN28 and AGS, demonstrating that CD10's ability to degrade gastrointestinal peptides plays a role in gastric cancer cell proliferation. Cell proliferation assays with enzyme inhibition International journal of oncology Low 15492809

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2018 CD10+GPR77+ Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness. Cell 1013 29395328
2017 Mature CD10+ and immature CD10- neutrophils present in G-CSF-treated donors display opposite effects on T cells. Blood 267 28053192
2000 CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. The American journal of surgical pathology 243 10843287
1981 Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage. Blood 240 6973348
2023 Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial. The Lancet. Oncology 171 38039991
1991 CD10 (CALLA)/neutral endopeptidase 24.11 modulates inflammatory peptide-induced changes in neutrophil morphology, migration, and adhesion proteins and is itself regulated by neutrophil activation. Blood 159 1717072
2004 Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet (London, England) 144 15464186
2002 CD10 is a marker for normal and neoplastic endometrial stromal cells. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 120 11781522
2005 Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: a tissue microarray study. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 113 15502805
2007 CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features. Blood 106 17138820
2023 Immunosuppressive CD10+ALPL+ neutrophils promote resistance to anti-PD-1 therapy in HCC by mediating irreversible exhaustion of T cells. Journal of hepatology 101 37689322
2002 Expression of CD10 by stromal cells during colorectal tumor development. Human pathology 93 12203213
2013 Tetraspanin protein CD9 interacts with metalloprotease CD10 and enhances its release via exosomes. The FEBS journal 92 23289620
2016 Mutations in MME cause an autosomal-recessive Charcot-Marie-Tooth disease type 2. Annals of neurology 83 26991897
1987 Phenotypic similarities and differences between CALLA-positive acute lymphoblastic leukemia cells and normal marrow CALLA-positive B cell precursors. Blood 78 2957002
2008 Evaluation of CD10 and procollagen 1 expression in atypical fibroxanthoma and dermatofibroma. The American journal of surgical pathology 72 18545147
2003 B-cell lymphomas with coexpression of CD5 and CD10. American journal of clinical pathology 70 12579992
2001 cDNA arrays and immunohistochemistry identification of CD10/CALLA expression in hepatocellular carcinoma. The American journal of pathology 70 11583969
2010 The CD10 enzyme is a key player to identify and regulate human mammary stem cells. Stem cells (Dayton, Ohio) 67 20506111
2007 Immunohistochemical staining of CD10 in atypical fibroxanthomas. Journal of cutaneous pathology 64 17448198
2004 CD10 expression in extranodal dissemination of angioimmunoblastic T-cell lymphoma. The American journal of surgical pathology 62 14707864
2004 Expression of CD10 in basal cell carcinoma. The American Journal of dermatopathology 61 15618927
2023 MME+ fibro-adipogenic progenitors are the dominant adipogenic population during fatty infiltration in human skeletal muscle. Communications biology 59 36707617
1994 CD10/NEP in non-small cell lung carcinomas. Relationship to cellular proliferation. The Journal of clinical investigation 56 7962523
2006 CD10 expression in trichoepithelioma and basal cell carcinoma. Journal of cutaneous pathology 55 16420307
1983 Distribution and modulation of a human leukemia-associated antigen (CALLA). Journal of immunology (Baltimore, Md. : 1950) 54 6225802
2004 The ectopeptidases CD10, CD13, CD26, and CD143 are upregulated in gastric cancer. International journal of oncology 53 15492809
2001 Decreased CD10 expression in grade III and in interfollicular infiltrates of follicular lymphomas. American journal of clinical pathology 53 11392883
2007 Differential expression of CD10 in prostate cancer and its clinical implication. BMC urology 52 17335564
2002 Expression of CD10 in malignant müllerian mixed tumors and adenosarcomas: an immunohistochemical study. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 52 12218209
2022 Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements. Blood advances 49 34654055
1998 CD10 expression in follicular lymphoma and large cell lymphoma is different from that of reactive lymph node follicles. Archives of pathology & laboratory medicine 49 9625422
2016 MME mutation in dominant spinocerebellar ataxia with neuropathy (SCA43). Neurology. Genetics 47 27583304
2016 Rare Variants in MME, Encoding Metalloprotease Neprilysin, Are Linked to Late-Onset Autosomal-Dominant Axonal Polyneuropathies. American journal of human genetics 47 27588448
2010 BCL6, MUM1, and CD10 expression in mantle cell lymphoma. Applied immunohistochemistry & molecular morphology : AIMM 47 19826251
2005 Stromal CD10 expression in mammary fibroadenomas and phyllodes tumours. Journal of clinical pathology 45 15677540
2005 CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia. Clinical lymphoma 45 15794857
2013 The Expression of CD10 and CD15 Is Progressively Increased during Colorectal Cancer Development. Korean journal of pathology 43 24009629
2008 Mantle cell lymphoma with aberrant expression of CD10. Histopathology 43 18518902
2012 EGFR, CD10 and proliferation marker Ki67 expression in ameloblastoma: possible role in local recurrence. Diagnostic pathology 42 22300665
2005 CD10 and BCL6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CD10+ T cells by flow cytometry. Human pathology 42 16084948
2010 Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence. Cancer biology & therapy 41 20574156
1992 The increase of low density subpopulations and CD10 (CALLA) negative neutrophils in severely infected patients. Surgery today 40 1392343
2004 CD10 expression in the female genital tract: does it have useful diagnostic applications? Advances in anatomic pathology 39 15505532
2019 CD10 expression identifies a subset of human perivascular progenitor cells with high proliferation and calcification potentials. Stem cells (Dayton, Ohio) 36 31721342
2015 CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples. Cancer cytopathology 36 26414904
2002 Induction of apoptosis and CD10/neutral endopeptidase expression by jaspamide in HL-60 line cells. Cellular and molecular life sciences : CMLS 36 12363040
2003 Analysis of CD10+ hairy cell leukemia. American journal of clinical pathology 35 12931553
2003 Benign CD10-positive T cells in reactive lymphoid proliferations and B-cell lymphomas. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 34 13679451
1993 Expression of CALLA/CD10 on human melanoma cells. Melanoma research 34 8292887
2012 Genetic variation in MME in relation to neprilysin protein and enzyme activity, Aβ levels, and Alzheimer's disease risk. International journal of molecular epidemiology and genetics 31 22493749
2011 CD10 and ICOS expression by multiparametric flow cytometry in angioimmunoblastic T-cell lymphoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 31 21499231
2005 Overexpression of CD10 and reduced MUC2 expression correlate with the development and progression of colorectal neoplasms. Pathology, research and practice 30 15901128
2023 FAP, CD10, and GPR77-labeled CAFs cause neoadjuvant chemotherapy resistance by inducing EMT and CSC in gastric cancer. BMC cancer 29 37277751
2013 Prostate cancer cell phenotypes based on AGR2 and CD10 expression. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 29 23348903
1997 CD10 in acute leukemias. GEIL (Groupe d'Etude Immunologique des Leucémies). Haematologica 28 9175328
2020 The genetic landscape of axonal neuropathies in the middle-aged and elderly: Focus on MME. Neurology 27 33144514
2019 Membrane Metalloendopeptidase (MME) Suppresses Metastasis of Esophageal Squamous Cell Carcinoma (ESCC) by Inhibiting FAK-RhoA Signaling Axis. The American journal of pathology 27 31054987
2018 Stromal CD10 expression in breast cancer correlates with tumor invasion and cancer stem cell phenotype. BMC cancer 27 29306324
2023 Ferroptosis of CD163+ tissue-infiltrating macrophages and CD10+ PC+ epithelial cells in lupus nephritis. Frontiers in immunology 26 37583695
2017 Aberrant expression of CD10 and BCL6 in mantle cell lymphoma. Histopathology 26 28628241
2007 Clinical relevance of neutral endopeptidase (NEP/CD10) in melanoma. Journal of translational medicine 26 17207277
2010 Natriuretic peptide pharmacogenetics: membrane metallo-endopeptidase (MME): common gene sequence variation, functional characterization and degradation. Journal of molecular and cellular cardiology 25 20692264
2004 Expression of CD13/aminopeptidase N and CD10/neutral endopeptidase on cultured human keratinocytes. Immunology letters 25 14757368
2020 Induced CD10 expression during monocyte-to-macrophage differentiation identifies a unique subset of macrophages in pancreatic ductal adenocarcinoma. Biochemical and biophysical research communications 23 32070494
1998 Human cytomegalovirus infection downregulates expression of the cellular aminopeptidases CD10 and CD13. Virology 23 9792845
2004 CD10 expression in diffuse large B-cell lymphomas does not influence survival. Virchows Archiv : an international journal of pathology 22 15517363
2009 CD10 AND CD34 expression in childhood acute lymphoblastic leukemia in Morocco: clinical relevance and outcome. Pediatric hematology and oncology 21 19437324
2007 CD10 expression in tumour and stromal cells of bladder carcinoma: an association with bilharziasis. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 21 18092952
1989 Human glioma cell lines expressing the common acute lymphoblastic leukemia antigen (cALLa) have neutral endopeptidase activity. International journal of cancer 21 2531122
2018 CD10, TDAG51, CK20, AR, INSM1, and Nestin Expression in the Differential Diagnosis of Trichoblastoma and Basal Cell Carcinoma. International journal of surgical pathology 20 29938548
2017 Screening of genetic variants in ADCYAP1R1, MME and 14q21 in a Swedish cluster headache cohort. The journal of headache and pain 20 28831700
2002 CD10 expression in non-small cell lung cancer. Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology 20 12122282
1989 CD10-(CALLA)-Positive Lymphocytes in Myeloma: Evidence that they are a Malignant Precursor Population and are of Germinal Centre Origin. Leukemia & lymphoma 20 27456402
1987 Multiple myeloma: the relationship between CALLA (CD10) positive lymphocytes in the peripheral blood and light chain isotype suppression. British journal of haematology 20 2959309
2011 CD10 expression helps to differentiate basal cell carcinoma from trichoepithelioma. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences 19 22279463
2003 Neutral endopeptidase/CD10 expression in the stroma of epithelial ovarian carcinoma. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 19 12649673
1988 Decreased expression of the common acute lymphoblastic leukaemia antigen (CALLA/CD10) on neutrophils from patients with thermal injury. British journal of haematology 19 2968812
2020 CD10 and p63 expression in a sarcomatoid undifferentiated melanoma: A cautionary (and molecularly annotated) tale. Journal of cutaneous pathology 18 31943331
2024 A comprehensive review of the literature on CD10: its function, clinical application, and prospects. Frontiers in pharmacology 17 38389922
2002 CD10 expression in primary intestinal large B-cell lymphomas: its clinical significance. Archives of pathology & laboratory medicine 17 12171495
2000 The expression and localization of neutral endopeptidase 24.11/CD10 in human gestational trophoblastic diseases. Laboratory investigation; a journal of technical methods and pathology 17 11092533
2020 Cancer stemness of CD10-positive cells regulated by Hedgehog pathway promotes the resistance to cisplatin in oral squamous cell carcinoma. Oral diseases 16 33037760
2016 CD10 down expression in follicular lymphoma correlates with gastrointestinal lesion involving the stomach and large intestine. Cancer science 16 27513891
2015 Study of Ki67 and CD10 expression as predictive factors of recurrence of ameloblastoma. European annals of otorhinolaryngology, head and neck diseases 16 26386615
2012 Anti-CD10 (56C6) expression in soft tissue sarcomas. Pathology, research and practice 16 22464152
2012 Copy number variation in ACHE/EPHB4 (7q22) and in BCHE/MME (3q26) genes in sporadic breast cancer. Chemico-biological interactions 16 23063927
2011 CD10 and osteopontin expression in dentigerous cyst and ameloblastoma. Diagnostic pathology 16 21609487
1987 Identification and characterization of a unique subpopulation (CALLA/CD10/negative) of human neutrophils manifesting a heightened chemotactic response to activated complement. Blood 16 2959334
2015 Mucinous phenotype and CD10 expression of primary adenocarcinoma of the small intestine. World journal of gastroenterology 15 25759539
2006 CD10 expression in peripheral T-cell lymphomas complicated by a proliferation of large B-cells. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 15 16400325
2023 Immunoregulatory functions of mature CD10+ and immature CD10- neutrophils in sepsis patients. Frontiers in medicine 14 36687441
2012 CD10 and E-cad expression in urinary bladder urothelial and squamous cell carcinoma. Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer 14 23339695
1991 CD10 and CD44 genes of leukemic cells and malignant cell lines show no evidence of transformation-related alterations. Journal of cellular physiology 14 1833412
2019 Immunohistochemical expression of Ki-67, p53, and CD10 in phyllodes tumor and their correlation with its histological grade. Journal of laboratory physicians 13 31929699
2015 Significance of androgen receptor and CD10 expression in cutaneous basal cell carcinoma and trichoepithelioma. Oncology letters 13 26788151
2005 Expression of CD10 and cytokeratins in ovarian and renal clear cell carcinoma. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 13 15968199
1997 CD10 is expressed on human thymic epithelial cell lines and modulates thymopentin-induced cell proliferation. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 13 9337153
2023 Chromosome level genome assembly of colored calla lily (Zantedeschia elliottiana). Scientific data 12 37689767
2017 Pax8, Napsin A, and CD10 as Immunohistochemical Markers of Canine Renal Cell Carcinoma. Veterinary pathology 12 28346124

Missed literature

Know a paper Affinage missed for MME? Flag it for the maintainers and the community.

No submissions yet.